Thomas Patrick Kelly bought $560k of XENE
Chief Financial Officer at Xenon Pharmaceuticals Inc.. 15,000 shares at an average of $37.32, traded Sep 30, 2026, filed Oct 1, 2026.
Score components
- +22RoleCFO
- +19Trade size$560k at market
- +8Relative to holdingsFirst purchase: no shares before this trade
- +18Price context2% above the 52-week low; 48% below the 52-week high
- +8Cluster2 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-410001, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 30, 2026 | POpen-market purchase Common Shares | +15,000 | $37.32 | $560k | 15,000 | 11 d ago |
Related signals
Other insiders at Xenon Pharmaceuticals Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 86Strong | Xenon Pharmaceuticals Inc. | Ian Mortimer PRESIDENT & CEO | $1.1M 30,000 shares | +151% | |
| 15Weak | XENEsell Xenon Pharmaceuticals Inc. | Steven Gannon director | $91 3 shares | -0% | |
| 49Moderate | XENEsell Xenon Pharmaceuticals Inc. | Sherry Aulin Chief Financial Officer | $771k 18,709 shares | -260% | |
| 17Weak | XENEsell Xenon Pharmaceuticals Inc. | Gary Patou director | $201k 4,891 shares | -19% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.